Eculizumab Treatment for Postpartum HELLP Syndrome and aHUS—Case Report

Näytä kaikki kuvailutiedot



Pysyväisosoite

http://hdl.handle.net/10138/315267

Lähdeviite

Lokki , A I , Haapio , M & Heikkinen-Eloranta , J 2020 , ' Eculizumab Treatment for Postpartum HELLP Syndrome and aHUS—Case Report ' , Frontiers in Immunology , vol. 11 , 548 . https://doi.org/10.3389/fimmu.2020.00548

Julkaisun nimi: Eculizumab Treatment for Postpartum HELLP Syndrome and aHUS—Case Report
Tekijä: Lokki, A. Inkeri; Haapio, Mikko; Heikkinen-Eloranta, Jenni
Tekijän organisaatio: Department of Bacteriology and Immunology
University of Helsinki
Helsinki University Hospital Area
TRIMM - Translational Immunology Research Program
Research Programs Unit
Department of Obstetrics and Gynecology
HUS Gynecology and Obstetrics
HUS Abdominal Center
Nefrologian yksikkö
Department of Medicine
Department of Medical and Clinical Genetics
Päiväys: 2020-04-03
Kieli: eng
Sivumäärä: 7
Kuuluu julkaisusarjaan: Frontiers in Immunology
ISSN: 1664-3224
DOI-tunniste: https://doi.org/10.3389/fimmu.2020.00548
URI: http://hdl.handle.net/10138/315267
Tiivistelmä: Preeclampsia is a pregnancy-specific disorder affecting ca 3% of all pregnant women. Preeclampsia is the source of severe pregnancy complications. Later life consequences for mother and infant include increased risk of cardiovascular disease. Preeclampsia is caused by the dysfunction of the endothelium with subsequent activation of complement and coagulation systems. HELLP syndrome is considered to be an extreme complication of preeclampsia but it can also present independently. Diagnostic symptoms in HELLP syndrome are Hemolysis, Elevated Liver enzymes, and Low Platelets. Similar phenotype is present in thrombotic microangiopathies (TMAs) and HELLP syndrome is considered part of the TMA spectrum. Here, we present a case of severe preeclampsia and HELLP syndrome, which exacerbated rapidly and eventually led to need of intensive care, plasma exchange, and hemodialysis. The patient showed signs of hemolysis, disturbance in the coagulation, and organ damage in liver and kidneys. After comprehensive laboratory testing and supportive care, the symptoms did not subside and treatment with complement C5 inhibitor eculizumab was started. Thereafter, the patient started to recover. The patient had pregnancy-induced aHUS. Earlier initiation of eculizumab treatment may potentially shorten and mitigate the disease and hypothetically decrease future health risks of preeclamptic women.
Avainsanat: 3123 Gynaecology and paediatrics
case report
preeclampsia
aHUS
eculizumab
HELLP
thrombotic microangiopathy
ELEVATED LIVER-ENZYMES
LOW PLATELET COUNT
THROMBOTIC MICROANGIOPATHY
COMPLEMENT ACTIVATION
ENDOTHELIAL FUNCTION
NORMAL-PREGNANCY
HEMOLYSIS
PREECLAMPSIA
WOMEN
LINK
Vertaisarvioitu: Kyllä
Tekijänoikeustiedot: cc_by
Pääsyrajoitteet: openAccess
Rinnakkaistallennettu versio: publishedVersion


Tiedostot

Latausmäärä yhteensä: Ladataan...

Tiedosto(t) Koko Formaatti Näytä
fimmu_11_00548.pdf 581.6KB PDF Avaa tiedosto

Viite kuuluu kokoelmiin:

Näytä kaikki kuvailutiedot